

Press release DD/MM/AAAA

# Thuasne launches five back braces for back pain conditions

# **Lomba**Stab range

Back braces with an easy-to-use and precise tightening system<sup>3</sup>!


Back pain has been called "the disease of the century" by the World Health. The impacts of low back pain go beyond the significant economic cost and have important repercussions on the quality of life.

Through its commitments and more than 40 years of expertise, Thuasne launches a new range of back braces from lumbar to thoraco-lumbar orthosis to accompany the patients in treatment of their back conditions in their daily life.

This new range brings innovation thanks to the integrated lacing system technology and the comfort it brings to the patients.

## A range for diverse lumbar conditions

Following the success of the first LombaStab brace launch in 2016, Thuasne is manufacturing today four new braces to cover more spine conditions <sup>1</sup>





#### High technicity for more comfort<sup>2</sup>

The new LombaStab products have been designed to answer each conditions¹ treatments challenge as well as the patients' everyday life needs. Easy and precise³, the tightening system combined with the specific elastic fabric allows to adapt the compression of the braces effortlessly depending on your need for an instant relief.

#### A new elegant design

Thuasne has been focus in improving the past years the comfort of its solutions thought commitment in research & development.

The design of the braces and the specific Combitex fabric used permit a pleasant wear all day long while insuring the proper adaptability to different morphologies. Within the same objective, the patented hand loops permit a symmetrical fitting around your spine, thereby ensuring a high degree of patient's compliance.



#### **About Thuasne**

Founded in 1847, Thuasne imagines, develops and manufactures medical devices allowing everyone to become active in its own health.

As a result of the shared history of 6 generations of entrepreneurs, the Group offers innovative, concrete and simple, suitable health solutions at the service of mobility.

Its expertise covers mainly the areas of orthopedics, medical compression and home support.

The company, with 2 100 employees, achieved a turnover of 215 million euros in 2017 which 40% international. The group is now present in 85 countries, through its 15 subsidiaries in Europe and the United States.

The products shown below are regulated medical devices that bear, under this regulation, the CE marking. LombaStab and LombaStab Vario are indicated for non-specific low back pain (acute, subacute and chronic) in patients between 60 cm and 140 cm in waist circumference. LombaStab High is indicated for non-specific low back pain (acute, subacute, chronic), lumbar spinal stenosis and spondylolysis. LombaStab immo is indicated for non-specific low back pain (acute, subacute, chronic), lumbar spinal stenosis, spondylolysis, post-op and Discopathy MODIC type 1. LombaStab dorso is indicated for stable traumatic vertebral fracture, stable osteoporotic vertebral fracture, Scheuermann's disease, static disorders (kyphosis or lordosis). Update: Janvier 2010. Read all instructions before use and seek advice from a qualified healthcare professional.



Thuasne – 120 rue Marius Aufan 92300 Levallois-Perret France. THUASNE DEUTSCHLAND GmbH -- Im Steinkamp 1230938 Burgwedel.



## Wings for your health

Press contact: Gilles Muller Re-active: gillesmuller@re-active.fr 01 40 22 63 19

1	<b>Lomba</b> Stab standard	<b>Lomba</b> Stab vario	<b>Lomba</b> Stab immo	<b>Lomba</b> Stab high	<b>Lomba</b> Stab dorso
Non-specific low back pain (acute, subacute, chronic)	Х	X	X	X	Х
Lumbar spinal stenosis	Х	Х	X	Х	
Spondylolysis			X	X	
Stabilization following surgery			X		
Discopathy MODIC type 1			X		
Stable traumatic vertebral fracture					Х
Stable osteoporotic vertebral fracture					X
Scheuermann's disease					Х
Static disorders (kyphosis or lordosis)					X

<sup>&</sup>lt;sup>2</sup>Less material at ribs and hips areas

<sup>&</sup>lt;sup>3</sup>Study conducted in-house on a panel de 13 people, July 2019